pembrolizumab
merck
['rcc,(-irccs),(-srcc),(-urcc)', 'knb61']
 reported 47.6% orr for len-pem in non-clear #rcc subtypes in #knb61. valuable academic study. supports use of len-pem. prcc sensitive (53%) activity in other subtypes, but small subgroups chrcc limited activity (13%) - len-eve seems the better choice 